Medtronic

MDT

Market cap $124B

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

In the last decade, Medtronic (MDT) stock has returned a notable $52 Bil back to its shareholders through cold, hard cash via dividends and buybacks. Let's look at some numbers and compare how this payout power stacks up against the market's biggest capital-return machines.

Medtronic (MDT) concluded the recent trading session at $96.5, signifying a -1.4% move from its prior day's close.

Medtronic plc - Special Call Company Participants Ryan Weispfenning - VP & Head of Investor Relations Emily Elswick Conference Call Participants Ryan Zimmerman - BTIG, LLC, Research Division Nathan Treybeck - Wells Fargo Securities, LLC, Research Division Christopher Pasquale - Nephron Research LLC Shagun Singh Chadha - RBC Capital Markets, Research Division Michael Polark - Wolfe Research, LLC Danielle Antalffy Presentation Ryan Weispfenning VP & Head of Investor Relations Okay. Hello, everyone.

TIME Best Inventions honors extraordinary innovations changing lives DUBLIN , Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first closed-loop DBS system for people with Parkinson's – has been recognized by TIME on its annual list of Best Inventions. There are over 10 million people living with Parkinson's disease globally,1 and while there is currently no cure, Medtronic deep brain stimulation (DBS) has been transforming the lives of people with Parkinson's and other neurological disorders for more than 30 years.

Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart disease Orchestra BioMed and Medtronic (NYSE: MDT) have a strategic collaboration to develop and commercialize AVIM Therapy for the treatment of uncontrolled hypertension in patients indicated for a pacemaker, an estimated global population of over 750,000 patients annually AVIM Therapy has received FDA Breakthrough Device Designation for the treatment of uncontrolled hypertension in patients with increased cardiovascular risk, an estimated U.S. population of over 7.7 million patients NEW HOPE, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced a data summary supporting the transformative potential of Atrioventricular Interval Modulation (“AVIM”) Therapy in the management of hypertensive heart disease will be presented in a keynote talk at the Georgia Innovation Summit in Tbilisi, Georgia on October 10, 2025.

First procedures completed and enrollment underway in Embrace Gynecology study, furthering the company's progress to expand minimally invasive treatment options to patients in the United States GALWAY, Ireland , Oct. 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced the start of the Embrace Gynecology investigational device exemption (IDE) U.S. clinical study to evaluate the safety and effectiveness of its Hugo™ robotic-assisted surgery (RAS) system in robotic-assisted gynecological procedures. The first procedures, total hysterectomies, were successfully completed at AHN West Penn Hospital in Pittsburgh, PA, by Dr. Sarah Crafton and Dr. Eirwen Miller, Embrace Gynecology study surgeons at Allegheny Health Network.

An “October Surprise” is usually a significant, late-breaking news event that generally occurs just before a November election and has the potential to influence its outcome.

Medtronic (MDT) closed the most recent trading day at $97.7, moving +2.33% from the previous trading session.

The number of surgeries performed by Intuitive Surgical's (ISRG -2.05%) da Vinci surgical robot rose 17% year over year in the second quarter of 2025 as the company placed 16% more da Vinci systems into service in the quarter than it did a year ago. And the total installed base of da Vinci systems rose 14% to 10,488 around the world.